Literature DB >> 6518451

Inhibition of human breast cancer cells by selenium.

A M Watrach, J A Milner, M A Watrach, K A Poirier.   

Abstract

The viability of human breast cancer cells (cell lines MCF-7 and MDA-MB 231) was inhibited in vitro in a dose-dependent manner by selenium supplementation. However, a normal diploid human cell line (MRC-5) was relatively resistant to selenium supplementation. The presence of selenium as Na2SeO3 at 1.1 X 10(-6) M reduced cancer cell viability by approximately 50%, whereas non-cancerous cells were not affected. Parenteral administration of sodium selenite also significantly inhibited the growth of the cancerous cell lines transplanted into nude mice. Selenium administration at 0.8 micrograms/g body wt resulted in an 80-93% reduction in the rate of tumor growth without apparent ill effects on the host.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6518451     DOI: 10.1016/s0304-3835(84)80024-5

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  Cellular selenoproteins and the effects of selenite on cell proliferation.

Authors:  J A Golczewski; G D Frenkel
Journal:  Biol Trace Elem Res       Date:  1989 Apr-May       Impact factor: 3.738

2.  Effect of selenium on the growth of three human colon cancer cell lines.

Authors:  J L Nano; D Czerucka; F Menguy; P Rampal
Journal:  Biol Trace Elem Res       Date:  1989 Apr-May       Impact factor: 3.738

3.  An elemental correlation study in cancerous and normal breast tissue with successive clinical stages by neutron activation analysis.

Authors:  A N Garg; V Singh; R G Weginwar; V N Sagdeo
Journal:  Biol Trace Elem Res       Date:  1994-12       Impact factor: 3.738

Review 4.  Selenium. Preclinical studies of anticancer therapeutic potential.

Authors:  G Batist
Journal:  Biol Trace Elem Res       Date:  1988 Jan-Apr       Impact factor: 3.738

5.  Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study.

Authors:  Ola Brodin; Staffan Eksborg; Marita Wallenberg; Charlotte Asker-Hagelberg; Erik H Larsen; Dag Mohlkert; Clara Lenneby-Helleday; Hans Jacobsson; Stig Linder; Sougat Misra; Mikael Björnstedt
Journal:  Nutrients       Date:  2015-06-19       Impact factor: 5.717

6.  Selenized milk casein in the diet of BALB/c nude mice reduces growth of intramammary MCF-7 tumors.

Authors:  Jenny M Warrington; Julie J M Kim; Priska Stahel; Scott R L Cieslar; Roger A Moorehead; Brenda L Coomber; Milena Corredig; John P Cant
Journal:  BMC Cancer       Date:  2013-10-23       Impact factor: 4.430

7.  Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7.

Authors:  Sang O Park; Young Bum Yoo; Yong Hun Kim; Kwang Je Baek; Jung-Hyun Yang; Pil Cho Choi; Jeong Hun Lee; Kyeong Ryong Lee; Kyoung Sik Park
Journal:  Ann Surg Treat Res       Date:  2015-01-27       Impact factor: 1.859

Review 8.  Antitumor Effects of Selenium.

Authors:  Seung Jo Kim; Min Chul Choi; Jong Min Park; An Sik Chung
Journal:  Int J Mol Sci       Date:  2021-10-31       Impact factor: 5.923

9.  The solvent and treatment regimen of sodium selenite cause its effects to vary on the radiation response of human bronchial cells from tumour and normal tissues.

Authors:  Katrin Manda; Stephan Kriesen; Guido Hildebrandt
Journal:  Med Oncol       Date:  2020-11-18       Impact factor: 3.064

10.  Selenium inhibits growth of trastuzumab-resistant human breast cancer cells via downregulation of Akt and beclin-1.

Authors:  Joohyun Woo; Jong Bin Kim; Taeeun Cho; Eun Hye Yoo; Byung-In Moon; Hyungju Kwon; Woosung Lim
Journal:  PLoS One       Date:  2021-09-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.